Cure My Disease

Don't miss your cure!

 Log in / Sign up

Radioactive tracer homes in on a protein tumors use to survive low oxygen

NCT ID NCT07833085

NEW Diagnosis Sponsor: Zhongnan Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 22, 2026 · Last updated Sep 22, 2026

Summary

Researchers are testing a PET/CT scan that uses a radioactive tracer called 68Ga-CAIX to detect solid tumors. The tracer binds to CAIX, a protein that many solid tumors produce when oxygen is scarce. The study enrolls about 100 adults with suspected or confirmed solid tumors, including kidney, lung, and breast cancers. Participants receive the tracer by vein and then undergo a scan 30 to 60 minutes later. The team compares scan results with tumor tissue to see whether the imaging can find primary and metastatic lesions and whether tracer uptake reflects CAIX levels in the tumor.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
68Ga-CAIX, a radioactive tracer that binds to the protein CAIX on tumor cells
What this could lead to
If it works, this scan could give doctors another way to find primary and metastatic solid tumors and to gauge how much CAIX a tumor carries.
What could go wrong
The tracer is experimental, so its images may miss some tumors or light up non-cancerous tissue. Results from 100 people may not apply to everyone, and the scan cannot replace a tissue biopsy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Dec 2031

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participants with suspected malignant solid tumors or patients with newly diagnosed or recurrent/metastatic malignant solid tumors confirmed by histopathology; * Age of 18 years and above, both male and female are eligible; * The ECOG PS score for physical condition in the Eastern Cancer Collaboration Group is 0-1 points; * Research participants voluntarily sign informed consent forms or have their parents/children/legal guardians sign informed consent forms, and are able to complete the trial according to the requirements of the research protocol. Exclusion Criteria: * Participants with severe liver and kidney dysfunction and cardiac dysfunction; * Participants with severe obesity, claustrophobia, or other reasons who are unable to undergo PET scans; * Pregnant or lactating women; * Other situations that researchers believe should be excluded and documented.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm cancer lung cancer lung neoplasm neoplasm non-small cell lung carcinoma nonpapillary renal cell carcinoma renal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast cancer Clear cell renal cell carcinoma Lung cancer (NSCLC) Malignant solid tumors

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Zhongnan hospital of Wuhan University

    Wuhan, Hubei, 430071, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.